Received May 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| ANTH | ANTHRAX (BIOTHRAX) | EMERGENT BIOSOLUTIONS | 1 | 300216A | IM / LA |
| TYP | TYPHOID VI POLYSACCHARIDE (TYPHIM VI) | SANOFI PASTEUR | 1 | Y2A021M | IM / RA |
| YF | YELLOW FEVER (YF-VAX) | SANOFI PASTEUR | 1 | UK134AA | SC / LA |
Pt reported to clinic several hours post-vaccine administration c/o Hives and itchiness that started on inner aspect of L arm that traveled to his L axilla. Pt. "brushed it off" and continued with his workday until he noticed hives to be getting worse and spreading to his trunk, abdomen and R arm/axilla. S/sx of anaphylaxis assessed but where found to be unremarkable and patient to be in stable condition. Pt. denies SOB, difficulty breathing, Tachypnea or cool clammy skin, feelings of impending doom. RN and MD called in to assess patient per protocol and ordered 50mg of Benadryl, PO to be administered. Orders carried out with patient endorsing improvement 30 minutes after Rx administration, skin still showing hives. MD educated patient on ER precautions and encouraged OTC allergy meds to be sought out for symptom management. Pt verbalized agreement to care plan and all education provided by medical staff. Pt left clinic; ambulatory and in stable condition.
NONE
NONE
NONE
NKDA
N/a